US Patent Issued to SK BIOPHARMACEUTICALS on April 14 for "Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl carbamate in combination therapy" (New Jersey Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,599,585, issued on April 14, was assigned to SK BIOPHARMACEUTICALS Co. LTD. (Gyeonggi-do, South Korea).

"Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl carbamate in combination therapy" was invented by Marc Kamin (South Fair Lawn, N.J.) and Laurent Vernillet (South Fair Lawn, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy."

The patent was filed on April 13, 2023, under Application No. 18/134,203.

*Fo...